Clinical Trials Browser

Neoplasm Metastasis × Paclitaxel × Breast × Clear all

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT07007559 2026-02-03

ASPEN-09

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT01898117 2025-11-26

Triple-B

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03841747 2024-03-12

PELICAN

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT02954055 2024-02-26

METEORA-II

Phase 2 Completed

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1 Withdrawn

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT02983045 2023-03-13

PIVOT-02

Phase 1/2 Completed

557 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02824575 2022-04-04

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01495247 2020-12-08

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT02628132 2020-07-07

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00876395 2018-12-19

BOLERO-1

Phase 3 Completed

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02929576 2018-10-22

ENDEAR

Phase 3 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT00707707 2018-03-06

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01512199 2017-10-18

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02474186 2017-08-03

Phase II Study for Solid Metastatic Tumors

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00561119 2017-05-01

Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01572727 2017-03-09

BELLE-4

Phase 2/3 Completed

416 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01069796 2016-03-17

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00900627 2016-01-20

THYME

Phase 1/2 Completed

330 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00426556 2015-12-28

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase 1 Completed

88 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00511459 2015-10-29

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00301730 2015-04-28

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01003158 2014-07-10

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00322400 2013-07-31

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00048893 2012-04-13

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1/2 Terminated

37 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00448305 2012-01-05

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT01169870 2012-01-04

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis